We are live on !
Find out more
Foresite Capital Management VI Portfolio holdings
AUM
$643M
Turnover
40%
1-Year Est. Return
343.43%
This Fund
S&P 500
This Quarter Est. Return
+21.58%
1 Year Est. Return
+343.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$643M
AUM Growth
+$182M
(+40%)
Cap. Flow
+$95.6M
Cap. Flow % of AUM
Cap. Flow %
14.88%
Top 10 Holdings %
Top 10 Hldgs %
81.55%
Holding
25
New
8
Increased
6
Reduced
1
Closed
2
Avg Time Held
0.5
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Seaport Therapeutics
SPTX
|
+$31.3M |
| 2 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$27.6M |
| 3 |
Celldex Therapeutics
CLDX
|
+$18.2M |
| 4 |
GH Research
GHRS
|
+$13M |
| 5 |
Jade Biosciences
JBIO
|
+$11.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$54.2M |
| 2 |
OnKure Therapeutics
OKUR
|
+$5.99M |
| 3 |
Minerva Neurosciences
NERV
|
+$5.51K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.5% |
| 2 | Financials | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$5.73B
| $168M | 26.2% |
2,369,574
+148,100
| +7% | +$9.7M |
2024 Q4
6 quarters
|
|
2
Alumis Inc
ALMS
$871M
| $120M | 18.6% |
4,247,670
| – | – |
2024 Q4
6 quarters
|
|
|
3
Seaport Therapeutics
SPTX
$1.05B
| $38.7M | 6.02% |
+1,779,521
| New | +$31.3M |
2026 Q2
0 quarters
|
|
4
Denali Therapeutics
DNLI
$3.03B
| $35.9M | 5.59% |
1,396,771
+186,800
| +15% | +$3.84M |
2025 Q3
3 quarters
|
|
|
5
Celldex Therapeutics
CLDX
$2.36B
| $32.7M | 5.09% |
879,713
+563,800
| +178% | +$18.2M |
2026 Q1
1 quarter
|
|
6
Agios Pharmaceuticals
AGIO
$1.82B
| $29.1M | 4.53% |
785,000
+260,000
| +50% | +$7.89M |
2025 Q4
2 quarters
|
|
7
Corvus Pharmaceuticals
CRVS
$844M
| $27.4M | 4.26% |
1,831,233
| – | – |
2024 Q4
6 quarters
|
|
|
PBLS
8
Parabilis Medicines Inc
PBLS
$3.5B
| $27.3M | 4.26% |
+999,044
| New | +$27.6M |
2026 Q2
0 quarters
|
|
|
9
GH Research
GHRS
$1.43B
| $25.3M | 3.93% |
940,493
+625,001
| +198% | +$13M |
2026 Q1
1 quarter
|
|
|
10
Jade Biosciences
JBIO
$894M
| $19.7M | 3.07% |
886,667
+566,667
| +177% | +$11.8M |
2026 Q1
1 quarter
|
|
11
Hinge Health
HNGE
$9.22B
| $18.3M | 2.85% |
220,400
| – | – |
2025 Q2
4 quarters
|
|
12
Kymera Therapeutics
KYMR
$10.8B
| $16.8M | 2.61% |
146,332
| – | – |
2024 Q4
6 quarters
|
|
13
DELISTED
AtaiBeckley Inc
ATAI
| $14.5M | 2.26% |
2,750,000
| – | – |
2025 Q4
2 quarters
|
|
14
Verastem
VSTM
$1.18B
| $12M | 1.87% |
3,146,631
| – | – |
2025 Q2
4 quarters
|
|
15
Beam Therapeutics
BEAM
$2.81B
| $11.3M | 1.76% |
+330,000
| New | +$10M |
2026 Q2
0 quarters
|
|
|
16
Minerva Neurosciences
NERV
$111M
| $11M | 1.72% |
1,985,584
-1,016
| -0.1% | -$5.51K |
2026 Q1
1 quarter
|
|
17
ArriVent BioPharma
AVBP
$733M
| $10.5M | 1.63% |
+301,341
| New | +$8.89M |
2026 Q2
0 quarters
|
|
18
Aura Biosciences
AURA
$637M
| $9.47M | 1.47% |
+1,333,334
| New | +$9.5M |
2026 Q2
0 quarters
|
|
19
DELISTED
Crinetics Pharmaceuticals
CRNX
| $7.93M | 1.23% |
212,010
| – | – |
2026 Q1
1 quarter
|
|
20
Research Alliance Corp III
RACC
$92.4M
| $3.21M | 0.5% |
+300,000
| New | +$3.13M |
2026 Q2
0 quarters
|
|
21
Zura Bio
ZURA
$389M
| $2.66M | 0.41% |
450,000
| – | – |
2026 Q1
1 quarter
|
|
22
Kailera Therapeutics
KLRA
$1.67B
| $826K | 0.13% |
+37,500
| New | +$824K |
2026 Q2
0 quarters
|
|
23
Disc Medicine
IRON
$3.59B
| $70.9K | 0.01% |
+970
| New | +$66.7K |
2026 Q2
0 quarters
|
|
|
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-1,364,019
| Closed | -$54.2M | – |
|
|
25
OnKure Therapeutics
OKUR
$106M
| – | – |
-1,445,783
| Closed | -$5.99M | – |
|
Similar funds
Foresite Capital Management VI's Q2 2026 Portfolio in Review
As of Q2 2026, Foresite Capital Management VI held 25 positions worth $643M, up 40% from $460M the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Foresite Capital Management VI deployed $95.6M of net new capital in Q2 2026, opening 8 new positions and adding to 6 existing holdings. Its largest new stake was Seaport Therapeutics: 1,779,521 shares worth $38.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Minerva Neurosciences, an estimated $5.51K trimmed.
- Foresite Capital Management VI's largest Q2 2026 buy was Seaport Therapeutics: 1,779,521 shares worth $38.7M.
- Foresite Capital Management VI added most to Celldex Therapeutics in Q2 2026, an estimated $18.2M increase.
- Foresite Capital Management VI's biggest Q2 2026 reduction was Minerva Neurosciences, cutting an estimated $5.51K.
- Foresite Capital Management VI fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $54.2M.
- Foresite Capital Management VI's ten largest holdings make up 82% of its $643M portfolio in Q2 2026.
- Foresite Capital Management VI opened 8 new positions and closed 2 in Q2 2026.
- Foresite Capital Management VI's portfolio value rose 40% quarter-over-quarter to $643M.
Based on Foresite Capital Management VI's 13F filing for Q2 2026, filed 14 Aug 2026.